HOME > About Walvax > Product

Group ACYW135 Meningococcal Polysaccharide Vaccine

 Market Approval time
The product was on market officially in March23, 2012
Group ACYW135 Meningococcal Polysaccharide Vaccineis a preparation of purified capsular polysaccharide antigens extracted from the cultures of Neisseria meningitidis group A, C, Y, and W135 respectively and lyophilized after addition of appropriate lactose as stabilizer. Itis presented asa white loose pellet. After reconstitution with accompanied vaccine diluent, it shall immediately turn into a clear liquid.
Active constituent: Neisseria meningitidis group A, C, Y and W135 capsular polysaccharides.
Excipients: Sodium chloride, lactose.
Diluent: Sterile water for injection.

The vaccine is indicated for active immunization to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y and W135. It is approved for usein individuals ≧2 years of age as follows:
 People travelling to or living in high risk areas, e.g. the Sahara region of Africa (Epidemic area of Neisseria meningitidis group A, C, Y and W135 infection).
 People who are engaged in laboratory work or vaccine manufacturing and may be exposed to Neisseria meningitidis group A, C, Y and W135 through air.
The vaccine does not prevent diseases caused by other groups of Neisseria meningitidis.

The vaccine is administered as a single 0.5 ml dose by subcutaneous injection in the deltoid region.
Primary immunization consisting one injection shall be carried out before the epidemic season of epidemic cerebrospinal meningitis. For the high risk individuals in epidemic areas, especially children vaccinated for the first dose before 4 years old, if they are under continuous high risk conditions, a booster dose shall be considered 2 to 3 years after the primary immunization. Although whether the older children and adults need the booster immunization is still to be determined, if the antibody level decreases quickly 2 to 3 years after the primary immunization, booster immunization within 3 to 5 years after the primary immunization shall be considered.

Vial. 1 dose.Each lyophilized vaccine is accompanied with 1 vial of 0.5ml diluent.

24 months.

免责声明: 本站资料及图片来源互联网文章,本网不承担任何由内容信息所引起的争议和法律责任。所有作品版权归原创作者所有,与本站立场无关,如用户分享不慎侵犯了您的权益,请联系我们告知,我们将做删除处理!